| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cardiomyopathy, Hypertrophic | 11 | 2019 | 193 | 1.90 | Why? |
| Endocarditis, Bacterial | 6 | 2019 | 344 | 1.50 | Why? |
| Endocarditis | 6 | 2019 | 368 | 1.13 | Why? |
| Denmark | 23 | 2021 | 2654 | 0.98 | Why? |
| Administration, Oral | 2 | 2019 | 2340 | 0.88 | Why? |
| Administration, Intravenous | 3 | 2019 | 1115 | 0.85 | Why? |
| Genes, Dominant | 1 | 2018 | 18 | 0.78 | Why? |
| Ablation Techniques | 5 | 2019 | 54 | 0.76 | Why? |
| Cardiac Conduction System Disease | 1 | 2018 | 44 | 0.74 | Why? |
| Osteomyelitis | 1 | 2019 | 131 | 0.69 | Why? |
| Ethanol | 5 | 2019 | 533 | 0.60 | Why? |
| Pacemaker, Artificial | 6 | 2019 | 431 | 0.60 | Why? |
| Losartan | 1 | 2015 | 86 | 0.58 | Why? |
| Masks | 3 | 2020 | 8528 | 0.52 | Why? |
| Electrocardiography | 9 | 2019 | 3957 | 0.50 | Why? |
| Exercise Tolerance | 1 | 2015 | 634 | 0.41 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 520 | 0.41 | Why? |
| Heart Septum | 3 | 2019 | 29 | 0.41 | Why? |
| Heart Valve Diseases | 3 | 2019 | 355 | 0.40 | Why? |
| Defibrillators, Implantable | 5 | 2019 | 624 | 0.40 | Why? |
| Anti-Bacterial Agents | 5 | 2019 | 10083 | 0.39 | Why? |
| Arrhythmias, Cardiac | 4 | 2018 | 2510 | 0.38 | Why? |
| Heart Defects, Congenital | 4 | 2019 | 933 | 0.37 | Why? |
| Ventricular Function, Left | 3 | 2018 | 1555 | 0.36 | Why? |
| alpha-Galactosidase | 2 | 2017 | 32 | 0.35 | Why? |
| Ventricular Outflow Obstruction | 2 | 2017 | 23 | 0.35 | Why? |
| Pedigree | 5 | 2018 | 502 | 0.32 | Why? |
| Ventricular Fibrillation | 2 | 2018 | 126 | 0.32 | Why? |
| Heart Valve Prosthesis Implantation | 3 | 2019 | 552 | 0.31 | Why? |
| Fabry Disease | 2 | 2017 | 106 | 0.31 | Why? |
| Hypertrophy, Left Ventricular | 2 | 2019 | 219 | 0.30 | Why? |
| Hypertension, Pregnancy-Induced | 2 | 2017 | 208 | 0.28 | Why? |
| Tachycardia, Ventricular | 2 | 2017 | 251 | 0.27 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2020 | 5164 | 0.25 | Why? |
| Echocardiography | 5 | 2020 | 3661 | 0.25 | Why? |
| Death, Sudden, Cardiac | 2 | 2018 | 522 | 0.24 | Why? |
| Heart Valve Prosthesis | 3 | 2019 | 533 | 0.23 | Why? |
| Magnetic Resonance Imaging | 5 | 2018 | 6551 | 0.22 | Why? |
| Sudden Infant Death | 1 | 2019 | 12 | 0.20 | Why? |
| Bacteremia | 3 | 2019 | 1372 | 0.20 | Why? |
| Glutaminase | 1 | 2018 | 4 | 0.20 | Why? |
| Sarcomeres | 1 | 2018 | 7 | 0.19 | Why? |
| Staphylococcal Infections | 2 | 2019 | 1099 | 0.19 | Why? |
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2018 | 19 | 0.19 | Why? |
| Antiporters | 1 | 2017 | 11 | 0.18 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.18 | Why? |
| Gain of Function Mutation | 1 | 2018 | 54 | 0.18 | Why? |
| Atrioventricular Block | 1 | 2019 | 105 | 0.18 | Why? |
| Bundle-Branch Block | 1 | 2019 | 127 | 0.18 | Why? |
| Mitral Valve | 2 | 2019 | 342 | 0.18 | Why? |
| Technetium Tc 99m Exametazime | 1 | 2017 | 3 | 0.17 | Why? |
| Ryanodine Receptor Calcium Release Channel | 1 | 2017 | 16 | 0.17 | Why? |
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 56 | 0.17 | Why? |
| Isoenzymes | 1 | 2017 | 127 | 0.17 | Why? |
| Aortic Valve Stenosis | 2 | 2018 | 741 | 0.17 | Why? |
| Enzyme Replacement Therapy | 1 | 2017 | 65 | 0.17 | Why? |
| Torsades de Pointes | 1 | 2019 | 229 | 0.16 | Why? |
| Aortic Valve Insufficiency | 1 | 2018 | 136 | 0.16 | Why? |
| Intention to Treat Analysis | 1 | 2018 | 673 | 0.16 | Why? |
| Kaplan-Meier Estimate | 4 | 2019 | 4260 | 0.16 | Why? |
| Streptococcal Infections | 1 | 2019 | 255 | 0.15 | Why? |
| Ventricular Remodeling | 2 | 2018 | 349 | 0.15 | Why? |
| Loss of Function Mutation | 1 | 2017 | 244 | 0.15 | Why? |
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2017 | 131 | 0.14 | Why? |
| Middle Aged | 31 | 2020 | 270681 | 0.14 | Why? |
| Anti-Arrhythmia Agents | 1 | 2018 | 325 | 0.14 | Why? |
| Cardiomyopathy, Dilated | 1 | 2018 | 251 | 0.14 | Why? |
| Mutation, Missense | 2 | 2017 | 863 | 0.14 | Why? |
| Registries | 10 | 2019 | 12327 | 0.14 | Why? |
| DNA | 2 | 2018 | 778 | 0.14 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.14 | Why? |
| Sarcoidosis | 1 | 2018 | 271 | 0.14 | Why? |
| Drug Utilization | 1 | 2019 | 619 | 0.13 | Why? |
| Echocardiography, Doppler | 1 | 2015 | 269 | 0.13 | Why? |
| Forecasting | 2 | 2019 | 4492 | 0.13 | Why? |
| Female | 38 | 2020 | 380317 | 0.13 | Why? |
| Syndrome | 1 | 2018 | 1310 | 0.13 | Why? |
| Male | 37 | 2020 | 367725 | 0.13 | Why? |
| Primary Prevention | 1 | 2020 | 778 | 0.13 | Why? |
| Follow-Up Studies | 7 | 2019 | 17020 | 0.13 | Why? |
| Genetic Predisposition to Disease | 5 | 2019 | 4027 | 0.13 | Why? |
| Leukocytes | 2 | 2017 | 1046 | 0.12 | Why? |
| Oropharynx | 1 | 2021 | 1581 | 0.12 | Why? |
| Myotonic Dystrophy | 1 | 2012 | 51 | 0.12 | Why? |
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 669 | 0.12 | Why? |
| Adult | 25 | 2020 | 244371 | 0.12 | Why? |
| Humans | 47 | 2021 | 930598 | 0.12 | Why? |
| Contrast Media | 1 | 2018 | 1011 | 0.12 | Why? |
| DNA, Mitochondrial | 1 | 2013 | 163 | 0.12 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.11 | Why? |
| Decision Support Techniques | 1 | 2018 | 903 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.11 | Why? |
| Cardiac Rehabilitation | 1 | 2017 | 525 | 0.11 | Why? |
| Incidence | 7 | 2020 | 25622 | 0.10 | Why? |
| Aged | 20 | 2020 | 215776 | 0.10 | Why? |
| Heart Diseases | 2 | 2020 | 3503 | 0.10 | Why? |
| Haplotypes | 1 | 2013 | 853 | 0.10 | Why? |
| Long QT Syndrome | 1 | 2019 | 1047 | 0.10 | Why? |
| Risk Assessment | 8 | 2020 | 25439 | 0.10 | Why? |
| Heart-Assist Devices | 1 | 2018 | 812 | 0.10 | Why? |
| Stroke Volume | 2 | 2018 | 2153 | 0.10 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.09 | Why? |
| Exercise Test | 1 | 2015 | 911 | 0.09 | Why? |
| Recovery of Function | 2 | 2017 | 2461 | 0.09 | Why? |
| Heart Ventricles | 1 | 2017 | 1139 | 0.09 | Why? |
| Risk Factors | 16 | 2020 | 71621 | 0.09 | Why? |
| Cardiomyopathies | 1 | 2018 | 997 | 0.09 | Why? |
| Prosthesis-Related Infections | 1 | 2012 | 302 | 0.09 | Why? |
| Gram-Positive Bacterial Infections | 1 | 2012 | 323 | 0.09 | Why? |
| Genetic Variation | 2 | 2019 | 3919 | 0.09 | Why? |
| Predictive Value of Tests | 6 | 2020 | 9537 | 0.09 | Why? |
| Patient Readmission | 1 | 2017 | 1543 | 0.08 | Why? |
| Heterozygote | 2 | 2018 | 249 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| Heart Transplantation | 1 | 2017 | 1293 | 0.08 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.08 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 1458 | 0.08 | Why? |
| Whole Exome Sequencing | 2 | 2018 | 437 | 0.08 | Why? |
| Electric Countershock | 2 | 2018 | 284 | 0.07 | Why? |
| Adolescent | 11 | 2019 | 86841 | 0.07 | Why? |
| Observer Variation | 2 | 2019 | 622 | 0.07 | Why? |
| Genetic Association Studies | 2 | 2019 | 559 | 0.07 | Why? |
| Time Factors | 6 | 2018 | 31397 | 0.07 | Why? |
| DNA Mutational Analysis | 2 | 2017 | 581 | 0.07 | Why? |
| Cardiac Catheterization | 1 | 2012 | 882 | 0.07 | Why? |
| Treatment Outcome | 8 | 2019 | 51732 | 0.07 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.07 | Why? |
| Disease Susceptibility | 1 | 2017 | 4002 | 0.07 | Why? |
| Gene Frequency | 2 | 2019 | 1210 | 0.07 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.07 | Why? |
| Europe | 5 | 2018 | 12702 | 0.07 | Why? |
| Heart | 3 | 2018 | 1791 | 0.06 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.06 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.06 | Why? |
| Disease Progression | 3 | 2018 | 13580 | 0.06 | Why? |
| Postoperative Complications | 2 | 2019 | 5861 | 0.06 | Why? |
| Alleles | 2 | 2019 | 1557 | 0.06 | Why? |
| Infant, Newborn | 6 | 2019 | 23105 | 0.06 | Why? |
| Staphylococcus aureus | 2 | 2019 | 844 | 0.06 | Why? |
| Cardiology | 1 | 2017 | 2873 | 0.06 | Why? |
| Retrospective Studies | 12 | 2019 | 105322 | 0.06 | Why? |
| Child | 7 | 2018 | 70012 | 0.06 | Why? |
| Young Adult | 11 | 2019 | 93724 | 0.05 | Why? |
| Societies, Medical | 1 | 2017 | 6907 | 0.05 | Why? |
| Proportional Hazards Models | 3 | 2018 | 6543 | 0.05 | Why? |
| Cohort Studies | 6 | 2020 | 36005 | 0.05 | Why? |
| Length of Stay | 1 | 2018 | 11042 | 0.05 | Why? |
| Coagulase | 1 | 2019 | 44 | 0.05 | Why? |
| Mutation | 2 | 2018 | 12376 | 0.05 | Why? |
| Papillary Muscles | 1 | 2018 | 8 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Enterococcus faecalis | 1 | 2019 | 126 | 0.05 | Why? |
| Chloride-Bicarbonate Antiporters | 1 | 2017 | 5 | 0.05 | Why? |
| Cardiac Output, Low | 1 | 2018 | 31 | 0.05 | Why? |
| X Chromosome Inactivation | 1 | 2017 | 23 | 0.04 | Why? |
| Zebrafish Proteins | 1 | 2017 | 37 | 0.04 | Why? |
| Electrophysiological Phenomena | 1 | 2017 | 59 | 0.04 | Why? |
| RAW 264.7 Cells | 1 | 2018 | 316 | 0.04 | Why? |
| Scandinavian and Nordic Countries | 1 | 2017 | 96 | 0.04 | Why? |
| Retreatment | 1 | 2018 | 186 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Reproducibility of Results | 3 | 2019 | 11304 | 0.04 | Why? |
| Pregnancy Trimester, Second | 1 | 2018 | 314 | 0.04 | Why? |
| Blood Culture | 1 | 2019 | 308 | 0.04 | Why? |
| Parity | 1 | 2017 | 122 | 0.04 | Why? |
| Zebrafish | 1 | 2017 | 181 | 0.04 | Why? |
| Age Factors | 4 | 2019 | 21039 | 0.04 | Why? |
| Gene Knockdown Techniques | 1 | 2017 | 347 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2019 | 15421 | 0.04 | Why? |
| Prosthesis Implantation | 1 | 2018 | 261 | 0.04 | Why? |
| Action Potentials | 1 | 2017 | 368 | 0.04 | Why? |
| CHO Cells | 1 | 2018 | 831 | 0.04 | Why? |
| Cardiac Pacing, Artificial | 1 | 2017 | 160 | 0.04 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.04 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.04 | Why? |
| Electrocardiography, Ambulatory | 1 | 2017 | 204 | 0.04 | Why? |
| Cricetulus | 1 | 2018 | 936 | 0.04 | Why? |
| Fibrosis | 1 | 2018 | 800 | 0.03 | Why? |
| Proton Pump Inhibitors | 1 | 2019 | 377 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.03 | Why? |
| Antidepressive Agents | 1 | 2019 | 509 | 0.03 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Hydrogen-Ion Concentration | 1 | 2017 | 993 | 0.03 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.03 | Why? |
| Fibroblasts | 1 | 2017 | 839 | 0.03 | Why? |
| Genetics, Population | 1 | 2013 | 162 | 0.03 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.03 | Why? |
| Stillbirth | 1 | 2017 | 544 | 0.03 | Why? |
| Cell Membrane | 1 | 2017 | 743 | 0.03 | Why? |
| Aortic Valve | 1 | 2019 | 664 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.03 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.03 | Why? |
| Enterococcus faecium | 1 | 2012 | 95 | 0.03 | Why? |
| Sex Factors | 2 | 2019 | 11014 | 0.03 | Why? |
| Pregnancy | 3 | 2018 | 23879 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2017 | 912 | 0.03 | Why? |
| Prognosis | 3 | 2020 | 32490 | 0.03 | Why? |
| Propensity Score | 1 | 2019 | 2690 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2020 | 88759 | 0.03 | Why? |
| Cricetinae | 1 | 2018 | 3344 | 0.03 | Why? |
| Mental Health | 1 | 2017 | 15770 | 0.03 | Why? |
| Seroconversion | 1 | 2020 | 2515 | 0.03 | Why? |
| Bacteriological Techniques | 1 | 2012 | 239 | 0.02 | Why? |
| Sex Distribution | 1 | 2017 | 2083 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| Tomography, X-Ray Computed | 1 | 2015 | 25144 | 0.02 | Why? |
| Antifungal Agents | 1 | 2019 | 1828 | 0.02 | Why? |
| Heart Rate | 1 | 2018 | 1527 | 0.02 | Why? |
| Echocardiography, Transesophageal | 1 | 2012 | 447 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.02 | Why? |
| Genotype | 1 | 2019 | 4697 | 0.02 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.02 | Why? |
| Needs Assessment | 1 | 2017 | 2352 | 0.02 | Why? |
| Mitochondria | 1 | 2013 | 857 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.02 | Why? |
| Transcriptome | 1 | 2018 | 3466 | 0.02 | Why? |
| Survival Rate | 1 | 2019 | 9206 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.02 | Why? |
| Infant | 2 | 2018 | 30274 | 0.02 | Why? |
| Animals | 3 | 2018 | 78931 | 0.02 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Child, Preschool | 2 | 2018 | 36283 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.01 | Why? |
| Population Surveillance | 1 | 2019 | 4967 | 0.01 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| United Kingdom | 1 | 2019 | 18046 | 0.01 | Why? |
| Phylogeny | 1 | 2013 | 13341 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.01 | Why? |